12.22.25 -- How AI Is Rewriting Tech Transfer Timelines

The top five common cell line development pitfalls — scalability, stability, complexity, analytics, and tech transfer — can be avoided with experienced partners and integrated, predictive strategies.

It was imperative for a large European CMO producing multiple biologics to select the right product quality and value for each customer to comply with the August 2023 EU GMP Annex 1 revision.

Successful CDMO partnerships in sterile manufacturing depend on advanced laboratory capabilities, transparent collaboration, and integrated systems that transform challenges into advantages.

The difference between QbD as burden and QbD as advantage lies in critical thinking supported by structure — a hierarchy of metrics, toolsets, and tailored platforms.

Discover how diagnosing ribosome pausing sites and optimizing codon usage dramatically improves bispecific antibody titers, turning difficult-to-express candidates into viable therapeutics.

Learn how the advanced principles of process intensification can be applied to process and equipment design, increasing facility throughput, and ultimately offering a wide range of benefits to customers.

Blending pharmaceuticals and medical devices into a single product offers immense potential for patient care, but manufacturing these combination products presents unique hurdles.

See how a high-throughput microwell plate platform economically screens a model IgG1 mAb at 120 mg/ml across 96 formulations while minimizing protein use and maximizing data output.

Explore the challenges when moving a bioconjugate candidate from early development to clinic, along with integrated solutions for navigating this growing area of the biopharmaceutical industry.

In this report, we review concrete examples of projects across a global network that are contributing to the successful achievement of sustainability goals and aspirations.

Partner with a CMO that combines expertise, innovation, and trusted global capabilities to bring life-changing therapies to patients faster and more reliably.

Thinking about your mAb scale-up processes early on can help avoid common pitfalls. Cytiva’s Fast Trak scientists discuss factors that can influence a successful scale-up outcome.

By leveraging our proprietary non-viral gene insertion technology, GPEx® Lightning ensures rapid development timelines and high-yield production, making it an ideal solution for complex biologics.

GS Effex® has been engineered to lack the enzyme responsible for the addition of fucose, α1,6-fucosyltransferase. This industrially relevant cell line produces antibodies free of fucose.

You can count on our extensive scientific and manufacturing expertise, stringent quality standards, and highly responsive customer service to ensure timely delivery of your life-changing products.

We offer an end-to-end solution, covering every stage of biologic drug development, from early clone selection and small-scale manufacturing to process scale-up, large-scale production, and quality control.

BD Physioject Disposable Autoinjector offers a proven, user-friendly platform for self-injection, enhancing patient comfort, safety, and adherence across multiple chronic disease treatments globally.